Business Of Biotech

We love to hear from our listeners. Send us a message. Dr. Randy Schatzman, CEO at Bolt Biotherapeutics , discusses his company's adjustment to pandemic disruption on the fundraising trail. He walks us through the remote-fundraising strategy that landed Bolt's recent $93.5 million Series C financing round, and how the company is moving towards an IPO in spite of market, civil, and politi...

We love to hear from our listeners. Send us a message. OSE Immunotherapeutics CEO Alexis Peyroles joins The Business Of Biotech: Summer Executive Sessions to discuss myeloid cells' role in immunology, why a team of transplant specialists is key to his company's therapeutic development approach, and creating differentiation as a clinical-stage immunotherapy company in an ever-growing sea...

We love to hear from our listeners. Send us a message. Arrowhead Pharma CEO Christopher Anzalone, Ph. D. gives us the inside story on the stake his company claimed on the now re-burgeoning RNAi space, the indications his company is targeting beyond liver disease, and how it's addressing the development and process challenges that must be overcome to further progress RNAi beyond the liver. Acc...

We love to hear from our listeners. Send us a message. While Immunomedics CMO Loretta Itri, M.D. is no stranger to taking drugs across the commercial finish line in big pharma, her most recent win with TRODELVY was very, very different. Here, Dr. Itri shares insight on her small biopharma's first commercial launch, the manufacturing and regulatory challenges overcome to get there, and why ADC...

We love to hear from our listeners. Send us a message. Heat Biologics founder and CEO Jeff Wolf took a creative approach to building his organization. With the science behind his company's platform to activate immune responses against pathogenic or cancer antigens in place, he proceeded to structure the organization and its people in a strategic fashion to support that platform. Learn how he...

We love to hear from our listeners. Send us a message. Obsidian Therapeutics CEO Dr. Paul Wotton didn't let pandemic-induced workforce restrictions impede his biopharma's progress. Instead, his team developed a software system purpose-built for biotechs to manage personnel and equipment per ever-changing guidelines. On this episode of The Business Of Biotech: Summer Executive Sessions, W...

We love to hear from our listeners. Send us a message. The Business Of Biotech "Summer Executive Sessions" kick off with a candid conversation with Athersys CFO Ivor Macleod, who brings years of finance leadership at Roche, Merck, and other big pharmas to Athersys as the company readies its lead candidate for life beyond clinical trials. Join us for a discussion on how Macleod is applyin...

We love to hear from our listeners. Send us a message. A strategic departure from the biotech incubator requires the coordination of moving parts aplenty. Development timelines, seed funding, facilities development, and team dynamics are just a sampling of the critical aspects discussed here with multi-time founder and Zumutor Biologics CEO Kavitha Iyer Rodrigues. Access this and hundreds of episo...

We love to hear from our listeners. Send us a message. On this episode of The Business Of Biotech, we're talking with Vivek Ramaswamy, who launched Roivant Sciences—parent company to a full 20 biopharma companies with dozens of pre-clinical through phase 3 candidates in their collective pipelines—back in 2014. Spinning them all up so quickly has required a skillful approach to recruiting—and...

We love to hear from our listeners. Send us a message. This week's Business Of Biotech pod features Immuneering CEO Dr. Ben Zeskind, who launched his biotech on the back of creative financing in the throes of the Great Recession. A pivot into biopharma landed Immuneering a $20 million series A round to develop its pipeline--at the outset of the COVID-19 pandemic. Dr. Zeskind joins us for a ca...

We love to hear from our listeners. Send us a message. Leslie Williams is a multi-time biotech founder and board member who's honed her pitch-building skills to a fine point. On this episode of The Business Of Biotech, Williams shares best practices for building your pitch deck, how to draw out the nuance that makes your story unique, what to expect in your initial pitch session and follow-on...

We love to hear from our listeners. Send us a message. Every emerging biopharma company shares a common goal: creating value for its employees, its board, its investors, and ultimately, patients. Along the way, that value creation might get a boost from an IPO, a merger, an acquisition, or steady growth as a private entity. On this episode of The Business Of Biotech, we talk with Dr. Francois Nade...

We love to hear from our listeners. Send us a message. There are few better suited to advise the leaders of new and emerging biopharma companies on the building blocks of a biotech startup than Allan Shaw . That's why we chose Shaw to help us kick off our Business of Biotech podcast series with an overview of the episodes to come. In addition to his work on the financial front lines of severa...

We love to hear from our listeners. Send us a message. Produced by BioProcess Online, the Business Of Biotech serves as a resource for the leaders of new and emerging biopharmas. We've lined up an incredible group of guests to join us—all of them founders who have taken biotherapy ideas and successfully turned them into clinical realities. Here’s a preview of how the series, which is focused...